AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia
Portfolio Pulse from
AbbVie announced that its Phase 2 EMPOWER trials for emraclidine in treating schizophrenia did not meet their primary endpoint. The trials failed to show a significant improvement in symptoms compared to placebo, although the drug was well-tolerated.
November 11, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AbbVie's Phase 2 trials for emraclidine in schizophrenia did not meet primary endpoints, indicating no significant improvement over placebo. The drug was well-tolerated.
The failure to meet primary endpoints in the Phase 2 trials is a setback for AbbVie's emraclidine, potentially impacting investor confidence and short-term stock price negatively. However, the drug's tolerability may offer some hope for future development.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100